GTP-004

Drug Profile

GTP-004

Alternative Names: GTP 004

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Georgetown Translational Pharmaceuticals
  • Developer GT Biopharma
  • Class
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myasthenia gravis

Most Recent Events

  • 11 Sep 2017 Georgetown Translational Pharmaceuticals has been acquired and merged into GT Biopharma
  • 18 Aug 2017 GTP has patents pending for GTP-004 in USA
  • 08 Aug 2017 GTP has filed an orphan drug application in the US for the treatment of Myasthenia gravis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top